| |
Newsroom /
Medical
/
Medical
/
Gastrointestinal Disorder Therapeutics, Analysis and Forecasts to 2016
Gastrointestinal Disorder Therapeutics, Analysis and Forecasts to 2016
The Irritable Bowel Syndrome Market is a Fast Growing Market with Strong Pipeline Drugs with High Safety and Efficacy Profiles
kent,
sidcup,
United Kingdom
(prbd.net)
15/06/2010
"Gastrointestinal Disorder Therapeutics, Analysis and Forecasts to 2016"
GBI Research, the leading business intelligence provider, has released its latest research, “Gastrointestinal Disorder Therapeutics to 2016 – High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global gastrointestinal disorder therapeutics market. The report analyzes the markets for gastrointestinal disorder in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
The global gastrointestinal disorder therapeutics market generated approximately $25.6 billion in 2009. The market is anticipated to reach revenues of approximately $17.3 billion by 2016 after declining at a CAGR of -5.4% between 2009 and 2016. In 2010, the market is forecast to reach revenues of about $24.5 billion. From 2001, the market grew at a CAGR of 4.4% to reach $25.6 billion in 2009. The decline in the market is due to major drugs going off-patent in the Gastroesophageal Reflux Disease (GERD) market. Irritable bowel syndrome was one of the fastest growing segments. This growth is primarily attributed to a strong pipeline with more emerging therapies. The expected new drug launches will be priced highly and will capture a major share of the prescriptions. Hence the irritable bowel syndrome market is expected to reap large revenues with the increased uptake of these new drugs and the increased awareness of the disease in patients leading to increased treatment seeking rates at the early stages of the disease.
In the gastrointestinal sector, most of the companies coordinate their R&D activities in order to constantly expand their product pipelines with innovative drugs. Although there is a consistent and continuous threat from generics and other alternatives, companies in the gastrointestinal disorders sector are not reluctant to invest in R&D and are focused on offering new products to the market. There are more than 240 drugs in the gastrointestinal disorders pipeline. Phase II has the most pipeline drugs, accounting for 48% of the pipeline, while the Phase III, Phase I and preclinical stages of the pipeline accounted for 24%, 18% and 10%, respectively.
In 2008 and 2009, the gastrointestinal disorders sector witnessed numerous licensing agreements. With about 59 drug licensing agreements, it is evident that the gastrointestinal disorder therapeutics sector is on an enormous growth path in the development of novel therapeutics. There have been increasing numbers of licensing agreements for drugs in the approval stages. Geographically, the emerging nations will see strong growth and so the number of licensing agreements in these nations is expected to increase. Licensing agreements strengthen the financial stability of new players in the market and expand the potential of the major players involved in the deal.
Licensing agreements in the approval stages accounted for 30% of the licensing agreements. Most pharmaceutical companies find it beneficial to license a drug in the approval stage. Most of the licensing agreements were focused on co-promotion, distribution, adding a new product to their existing portfolio, marketing, and receiving full marketing rights for the originator product. Licensing agreements in the preclinical and drug discovery stage, Phase I, Phase II and Phase III accounted for 12%, 8%, 17% and 18%, respectively, of the licensing agreements.
Visit our report store: http://www.gbiresearch.com
About
GBI Research is a global market intelligence services company providing information research and analysis products and services.
|